Wo wir heute stehen und in welche Richtung bewegen wir uns: Integration von PI3K/AKT-Signalweg-gerichteten Therapien in die klinische Praxis für Hormonrezeptor-positiven/HER2-negativen fortgeschrittenen Brustkrebs (ABC)

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Onde estamos e para onde vamos: integração de terapêuticas dirigidas à via PI3K/AKT na prática clínica para o cancro da mama avançado com recetores hormonais positivos e HER2 negativo

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Där vi är idag och där vi är på väg: Integrering av PI3K/AKT-signalvägs–styrda behandlingsalternativ i kliniska praxis för patienter med hormonreceptor–positiv/HER2-negativ lokalt bröstcancer

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Situazione attuale e prospettive future: integrazione delle terapie mirate alla via di segnale PI3K/AKT nella pratica clinica per il carcinoma mammario avanzato positivo per i recettori ormonali e HER2-negativo

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Où nous en sommes et où nous allons : Intégration des thérapies ciblant la voie PI3K/AKT dans la pratique clinique pour le cancer du sein avancé à récepteurs hormonaux positifs/HER2 négatif

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Where We Are Today and Where We Are Going: Integrating PI3K/AKT Pathway–Directed Therapies Into Clinical Practice for Hormone Receptor–Positive/HER2-Negative Advanced Breast Cancer

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer

Content Format:

Podcast

Credit Type:

--

Credits:

--
Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer

Content Format:

Tool

Credit Type:

AMA | EBAC®

Credits:

0.25
Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ESMO Congress

Content Format:

Text Module

Credit Type:

AMA | EBAC®

Credits:

1.50
An Expert’s Guide to ESMO 2025: A Preview of the Top Abstracts

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Experts Discuss Evolving State-of-the-Art Management of Patients With HER2-Positive MBC

Content Format:

Podcast

Credit Type:

--

Credits:

--
Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

Content Format:

Video

Credit Type:

AMA

Credits:

0.75
Frequently Asked Questions in HER2-Positive Metastatic Breast Cancer Care

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Novel Anti-HER2–Targeted Tyrosine Kinase Inhibitors

Content Format:

Slideset

Credit Type:

--

Credits:

--
ExpressPoints: Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

Content Format:

Slideset

Credit Type:

--

Credits:

--